S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
NASDAQ:PCRX

Pacira BioSciences - PCRX Earnings Date, Estimates & Call Transcripts

$57.56
+1.30 (+2.31%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$56.15
$57.67
50-Day Range
$51.49
$62.34
52-Week Range
$45.05
$82.16
Volume
252,502 shs
Average Volume
510,818 shs
Market Capitalization
$2.62 billion
P/E Ratio
70.20
Dividend Yield
N/A
Price Target
$80.75

Earnings Summary

Upcoming
Earnings Date
Nov. 2Estimated
Actual EPS
(Aug. 3)
$0.51 Missed By -$0.34
Consensus EPS
(Aug. 3)
$0.85
Last Year's Q3 EPS
(8/2/2021)
$0.77
Skip Charts & View Estimated and Actual Earnings Data

PCRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PCRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Pacira BioSciences Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20222$0.52$0.63$0.58 
Q2 20222$0.63$0.87$0.75 
Q3 20222$0.66$0.82$0.74 
Q4 20222$0.80$1.03$0.92 
FY 20228$2.61$3.35 $2.98

PCRX Earnings Date and Information

Pacira BioSciences last released its quarterly earnings results on August 3rd, 2022. The reported $0.51 EPS for the quarter, missing analysts' consensus estimates of $0.85 by $0.34. The firm earned $169.41 million during the quarter, compared to the consensus estimate of $169.27 million. Its revenue for the quarter was up 24.9% on a year-over-year basis. Pacira BioSciences has generated $0.82 earnings per share over the last year ($0.82 diluted earnings per share) and currently has a price-to-earnings ratio of 70.2. Earnings for Pacira BioSciences are expected to grow by 76.53% in the coming year, from $2.13 to $3.76 per share. Pacira BioSciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 2nd, 2022 based off prior year's report dates.

Pacira BioSciences Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/2/2022
(Estimated)
        
8/3/2022Q2$0.85$0.51($0.34)$169.27 million$169.41 million      
5/4/2022Q1 2022$0.49$0.45($0.04)$0.75$155.08 million$157.99 million      
2/24/2022Q4 2021$0.60$0.78+$0.18$1.68$157.42 million$159.19 million    
11/2/20219/30/2021$0.65$0.72+$0.07$0.67$129.69 million$127.70 million    
8/2/20216/30/2021$0.74$0.77+$0.03$0.78$135.02 million$135.60 million      
5/3/20213/31/2021$0.64$0.53($0.11)$0.51$119.23 million$119.00 million  
2/24/202112/31/2020$0.81$0.87+$0.06$0.94$130.91 million$130.90 million  
10/29/20209/30/2020$0.65$0.68+$0.03($2.08)$115.95 million$117.50 million    
8/6/20206/30/2020$0.09$0.12+$0.03$0.09$75.57 million$75.50 million  
5/7/20203/31/2020$0.30$0.53+$0.23$0.47$101.64 million$105.68 million  
2/20/2020Q4 2019$0.21$0.56+$0.35$0.80$122.04 million$122.42 million    
11/7/2019Q3 2019$0.13$0.48+$0.35$0.67$104.88 million$104.69 million  
8/8/2019Q2 2019$0.14$0.41+$0.27$0.40$99.92 million$102.60 million    
5/2/20193/31/2019$0.02$0.22+$0.20$0.15$92.13 million$91.31 million  
2/28/2019Q4 2018$0.07$0.28+$0.21$0.36$93.69 million$95.12 million
11/1/20189/30/2018($0.09)$0.31+$0.40$0.24$79.87 million$83.45 million    
8/2/2018Q2 2018($0.13)$0.24+$0.37$0.08$77.53 million$84.10 million  
5/3/2018Q1 2018$0.02$0.02($0.10)$73.92 million$74.61 million  
2/28/2018Q4 2017($0.08)$0.38+$0.46$0.25$79.06 million$79.08 million  
11/8/2017Q3 2017($0.04)$0.11+$0.15($0.03)$68.99 million$67.30 million
8/2/2017Q2 2017($0.05)($0.11)($0.06)($0.09)$73.37 million$70.90 million  
5/4/2017Q1 2017($0.23)($0.19)+$0.04($0.24)$70.30 million$69.30 million  
3/1/2017Q4 2016($0.15)($0.12)+$0.03($0.13)$73.08 million$72.90 million  
11/2/2016Q316($0.02)$0.20+$0.22$67.16 million$68.40 million  
8/4/2016Q2 2016($0.20)($0.02)+$0.18$0.17$67.80 million$69.60 million  
5/2/2016Q1 2016($0.10)($0.08)+$0.02($0.06)$67.11 million$65.50 million  
2/25/2016Q4 2015$0.04($0.04)($0.08)($0.01)$68.40 million$69.30 million  
10/27/2015Q3 2015$0.03$0.10+$0.07$0.12$60.44 million$62.20 million  
7/30/2015Q2 2015$0.04$0.03($0.01)$0.06$62.97 million$59.10 million  
4/30/2015Q1 2015$0.02$0.05+$0.03$0.07$61.11 million$58.30 million  
2/24/2015Q4 2014$0.19$0.16($0.03)$0.18$61.62 million$61.80 million  
10/30/2014Q3 2014($0.01)($0.05)($0.04)($0.02)$52.20 million$52.00 million  
7/31/2014Q2 2014($0.24)($0.11)+$0.13($0.08)$42.20 million$47.20 million  
5/1/2014Q1 2014($0.30)($0.31)($0.01)($0.28)$35.40 million$36.70 million  
2/25/2014Q4 2013($0.31)($0.33)($0.02)($0.30)$30.72 million$33.56 million  
10/31/2013Q3 2013($0.36)($0.41)($0.05)($0.38)$22.10 million$23.30 million  
8/6/2013Q2 2013($0.43)($0.42)+$0.01($0.42)$16.45 million$17.14 million
5/8/2013Q1 2013($0.49)($0.61)($0.12)($0.51)$12.60 million$11.59 million
3/7/2013Q4 2012($0.41)($0.50)($0.09)($0.50)
11/1/2012Q312($0.44)($0.49)($0.05)$7.85 million$8.50 million
8/9/2012Q2 2012($0.43)($0.27)+$0.16($0.27)
5/9/2012Q1 2012($0.39)($0.47)($0.08)($0.47)
3/27/2012Q4 2011($0.54)($0.58)($0.04)($0.44)
10/31/2011Q3 2011($0.59)($0.55)+$0.04($0.55)
8/11/2011Q2 2011($0.58)($0.51)+$0.07($0.51)
5/11/2011Q1 2011($0.53)($0.98)($0.45)($0.98)
3/31/2011Q4 2010($11.95)($11.95)($11.63)












Pacira BioSciences Earnings - Frequently Asked Questions

When is Pacira BioSciences's earnings date?

Pacira BioSciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 2nd, 2022 based off last year's report dates. Learn more on PCRX's earnings history.

Did Pacira BioSciences beat their earnings estimates last quarter?

In the previous quarter, Pacira BioSciences (NASDAQ:PCRX) missed the analysts' consensus estimate of $0.85 by $0.34 with a reported earnings per share (EPS) of $0.51. Learn more on analysts' earnings estimate vs. PCRX's actual earnings.

How can I listen to Pacira BioSciences's earnings conference call?

The conference call for Pacira BioSciences's latest earnings report can be listened to online. Listen to Conference Call

How can I read Pacira BioSciences's conference call transcript?

The conference call transcript for Pacira BioSciences's latest earnings report can be read online. Read Transcript

How can I view Pacira BioSciences's earnings report?

Pacira BioSciences's earnings report can be found in their filing with the SEC. View SEC filing

How much revenue does Pacira BioSciences generate each year?

Pacira BioSciences (NASDAQ:PCRX) has a recorded annual revenue of $541.53 million.

How much profit does Pacira BioSciences generate each year?

Pacira BioSciences (NASDAQ:PCRX) has a recorded net income of $41.98 million. PCRX has generated $0.82 earnings per share over the last four quarters.

What is Pacira BioSciences's price-to-earnings ratio?

Pacira BioSciences (NASDAQ:PCRX) has a trailing price-to-earnings ratio of 70.20 and a forward price-to-earnings ratio of 27.02.

What is Pacira BioSciences's EPS forecast for next year?

Pacira BioSciences's earnings are expected to grow from $2.13 per share to $3.76 per share in the next year, which is a 76.53% increase.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:PCRX) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.